Physician profile
William R Powers
NPI 1871601377
$588.60
in general payments reported to CMS, 2019-2025
13 companies · $55.32 in 2025
The $55.32 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.30 · 2020: $37.47 · 2021: $36.89 · 2022: $105 · 2023: $30.58 · 2024: $286 · 2025: $55.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $372.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $128.66 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $87.83 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Kyowa Kirin, INC. | $56.56 | 2024-2025 | Crysvita |
| Novo Nordisk INC | $52.34 | 2022-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $45.70 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.25 | 2021-2024 | |
| Abbvie INC. | $39.17 | 2022-2024 | |
| Arbor Pharmaceuticals, INC. | $35.24 | 2020-2021 | |
| Braeburn INC. | $30.15 | 2024 | Brixadi |
| Glaxosmithkline, LLC. | $22.62 | 2024 | Arexvy |
| Xeris Pharmaceuticals, INC. | $21.06 | 2024 | Gvoke Hypopen |
| Baxter Healthcare | $15.86 | 2022 | |
| Pfizer INC. | $13.16 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.